T1	Participants 73 99	gastric carcinoma patients
T2	Participants 287 313	gastric carcinoma patients
T3	Participants 455 526	all the enrolled patients (30 in the control and 32 in the trial group)
T4	Participants 950 979	patients of blood stasis type
T5	Participants 1010 1061	patients of Pi-deficiency type or of damp-heat type
